Alzheimer's Disease International (ADI)
News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.
Lecanemab is the first therapy of its kind approved in the EU that could potentially slow the progression of Alzheimer’s disease. The use of lecanemab will now be considered by national payers, who will assess the treatment against further nationally determined criteria.
This comes as the Appeals board of the European Commission were unable to reach a verdict following the “no opinion” decision of the Standing Committee on Medicinal Products for Human Use and the European Commission. The matter will now be referred the European Commission for a final decision.
October signaled another busy month for ADI, with our and board members travelling internationally to capitalize on the growing momentum; from Buenos Aires, Brunei Darussalam, Helsinki, Lausanne, Tbilisi, to The Hague.
As World Alzheimer’s Month comes to a close, we reflect on some of the highlights from this year’s campaign
ADI member Dementia Australia has developed an app to help support brain health and encourage more timely dementia diagnoses.
As ADI prepares to attend the G7 summit in Hiroshima, Japan, DY Suharya writes about the journey of making dementia a priority at the G7 summit.
Silverado Senior Living is the first care home provider to receive ADI Accreditation since the launch of the accreditation programme in 2021.
Earlier this year, Alzheimer’s Disease Association of the Philippines partnered with Memory Lane Games to build a culturally relevant and customised cognitive game app for carers and people living with dementia in the Philippines.
In this blog, members of the ADI team look back at 2022 and write about their hopes and aspirations for 2023.
In this blog, the authors of 'Occupational Therapy and Dementia' discuss the importance of occupational therapy in better supporting people living with dementia, as well as raising awareness about reducing the risk of dementia.